Study
| Open-label, multicenter, phase 3 trial (EMPOWER-Cervical 1) |
| Recurrent or metastatic cervical carcinoma, progressed after prior platinum-containing therapy |
| Cemiplimab (n=304) or single-agent chemotherapy (n=304) |
Efficacy
| mOS: 12.0 mos vs. 8.5 mos; (HR: 0.69; P<0.001) |
| ORR: 16.4% vs 6.3% |
Safety
| Grade 3 AE >= 45% vs 53.4 |
| Anemia:12% vs 26.9%. Urinary tract infection 5.0% vs 2.8% |
N Engl J Med 2022; 386:544-555
Survival with Cemiplimab in Recurrent Cervical Cancer
http://doi.org/10.1056/NEJMoa2112187
Reviewed by Hasan Cagri Yildirim, MD on May 20, 2022
